about
Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertensionDiagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled MoleculesPlatelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in ratsThe beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in ratsInflammation in pulmonary arterial hypertension.Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension.Dexamethasone induces apoptosis in pulmonary arterial smooth muscle cells.Current insights on the pathogenesis of pulmonary arterial hypertension.Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension.Nuclear factor κ-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension.A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series).Bromodomain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension.Evidence for the involvement of type I interferon in pulmonary arterial hypertension.The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension.TLR4 signalling in pulmonary stromal cells is critical for inflammation and immunity in the airwaysTertiary lymphoid organs in infection and autoimmunity.Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay.Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first.Chemotherapy-induced pulmonary hypertension: role of alkylating agents.Potassium channels in pulmonary arterial hypertension.MicroRNA networks in pulmonary arterial hypertension: share mechanisms with cancer?T-type Ca2+ channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension.BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.Use of β-Blockers in Pulmonary Hypertension.Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease.Endothelial-to-Mesenchymal Transition: An Evolving Paradigm and a Promising Therapeutic Target in PAH.Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension.Rescuing BMPR2-driven endothelial dysfunction in PAH: a novel treatment strategy for the future?Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension.[Pulmonary arterial hypertension: a flavor of autoimmunity].Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension.[Physiopathology of pulmonary arterial hypertension. Cellular and molecular aspects].Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension.Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.Early Development of Right Ventricular Ischemic Lesions in a Novel Large Animal Model of Acute Right Heart Failure in Chronic Thromboembolic Pulmonary Hypertension.Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension.
P50
Q28243527-0D3DD9D9-C2FA-4F80-8DB4-7473D910FF56Q28818128-35571196-30BC-4C3C-9ABF-A1B60F5814ABQ33329056-2F862D95-B412-47EA-B44B-C8B7B4D6F291Q33786092-42D93C93-A644-4AC2-92DF-B88FE8DF236BQ35021663-9B8B480F-0616-4363-805C-E3BD9EBBBFA8Q35210445-3358CE8E-7758-4330-BD13-9827E791B9B0Q35289907-82E1C3B5-9EF1-4C37-AECB-20395C257361Q35779717-EDE964B1-7184-4C0B-A984-7D6F6B6B638EQ36240249-ADA36FB2-641F-4FA8-928F-592EE4AE7C74Q37209074-18DBA3CC-3449-47F2-B2FA-EBE2FBEA30D7Q37215728-4EFFC1A4-025D-4284-89F2-970AEC7FDA71Q37410202-3BB50457-2B37-47B8-BED5-9B30A5E0E65DQ37555457-8301E5DB-20B8-4FA2-8F19-AA65BDE0559FQ37561236-BECC8714-EF04-4EB8-98D8-D87F359F611DQ37735087-36B89D59-20FC-4480-9A79-54C620548E34Q37851851-6D4347EE-E513-447F-A767-014BD085BE7EQ37937745-DAEA3198-5D11-48DB-85A0-A671532C79D8Q38012568-B164FF29-0026-4175-9B32-3B886D7CE6C5Q38137789-56F03993-7E2D-473C-84B2-A44BBACE665EQ38198974-89FD9833-9C88-4B23-B932-F40861D37254Q38205687-F20FF5D8-677D-4B1E-A15C-9AD08F4B4B31Q38286586-A93B712B-C930-45EE-A4C4-146B1E97D16EQ38581241-43F1382C-BBE3-4E42-9A00-7587779D578CQ38633854-1A619CDF-14E7-4273-A0E6-0A33E8A723FFQ38706299-DB744B47-DA45-4119-9530-DCE62BC17866Q38732718-78AFC629-4173-493D-B634-46DFFA65E65DQ39212213-B5483CF1-504B-47F2-AF25-3A0434BC9647Q40351526-4754ABBF-5AD9-48AF-AC0A-FEAED7FFA13FQ41557241-29CF83AB-4BD1-4426-BDFC-817A56A5A642Q41593009-861047E0-891D-4CD7-8E5D-E0DAA6509B96Q42332332-F81C5CAB-FD9E-48DC-9DBD-A98AD6472CC0Q42841280-1D6FDACB-172B-44AF-8135-6B4378B11F72Q43717280-E518091A-717C-4D4B-AF2E-4DBF1CB81FD7Q46277870-45104644-920D-4F4E-9167-B6E020F54B38Q46411179-AD4479DC-50C7-43D4-A6A9-DA7519B894F1Q46617580-8A1324BF-1DD7-4006-B284-9305E3435CD0Q46682354-EC8449E8-CAF3-4451-9230-BE7A3EA66851Q46738805-307FEC3C-FA85-4566-B392-8BA707BC2F47Q47434868-42434001-6452-4771-B8FD-F67B9E1E0C20Q47649958-07CA3DD2-CAF0-4EB3-9C95-2A05F14CA483
P50
description
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Frédéric Perros
@ast
Frédéric Perros
@en
Frédéric Perros
@es
Frédéric Perros
@nl
type
label
Frédéric Perros
@ast
Frédéric Perros
@en
Frédéric Perros
@es
Frédéric Perros
@nl
prefLabel
Frédéric Perros
@ast
Frédéric Perros
@en
Frédéric Perros
@es
Frédéric Perros
@nl
P214
P106
P21
P214
P31
P496
0000-0001-7730-2427
P735
P7859
viaf-190776351